Importance of the terminal portion of tumor time-activity curve in determining tumor dosimetry in radioimmunotherapy

J Nucl Med. 1991 Jun;32(6):1314-5.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Lymphoma, B-Cell / therapy*
  • Radiotherapy Dosage

Substances

  • Antibodies, Monoclonal
  • Iodine Radioisotopes